Assembly Biosciences, Inc. (ASMB)
22.19
-0.31
(-1.38%)
USD |
NASDAQ |
Nov 20, 16:00
22.26
+0.07
(+0.32%)
After-Hours: 20:00
Assembly Biosciences Enterprise Value : 139.92M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 139.92M |
| November 19, 2026 | 146.23M |
| November 18, 2026 | 143.99M |
| November 17, 2026 | 146.23M |
| November 16, 2026 | 121.59M |
| November 13, 2026 | 118.13M |
| November 12, 2026 | 98.98M |
| November 11, 2026 | 143.59M |
| November 10, 2026 | 122.81M |
| November 09, 2026 | 131.77M |
| November 06, 2026 | 103.87M |
| November 05, 2026 | 95.31M |
| November 04, 2026 | 92.67M |
| November 03, 2026 | 93.68M |
| November 02, 2026 | 85.33M |
| October 30, 2026 | 97.96M |
| October 29, 2026 | 112.83M |
| October 28, 2026 | 106.92M |
| October 27, 2026 | 101.42M |
| October 26, 2026 | 88.59M |
| October 23, 2026 | 92.05M |
| October 22, 2026 | 101.02M |
| October 21, 2026 | 104.68M |
| October 20, 2026 | 119.55M |
| October 19, 2026 | 98.57M |
| Date | Value |
|---|---|
| October 16, 2026 | 97.15M |
| October 15, 2026 | 106.92M |
| October 14, 2026 | 106.11M |
| October 13, 2026 | 102.24M |
| October 12, 2026 | 151.73M |
| October 09, 2026 | 167.21M |
| October 08, 2026 | 152.75M |
| October 07, 2026 | 155.40M |
| October 06, 2026 | 139.72M |
| October 05, 2026 | 151.12M |
| October 02, 2026 | 147.05M |
| October 01, 2026 | 156.01M |
| September 30, 2026 | 166.40M |
| September 29, 2026 | 148.07M |
| September 28, 2026 | 150.65M |
| September 25, 2026 | 151.85M |
| September 24, 2026 | 151.65M |
| September 23, 2026 | 157.80M |
| September 22, 2026 | 187.18M |
| September 21, 2026 | 186.98M |
| September 18, 2026 | 177.65M |
| September 17, 2026 | 185.00M |
| September 16, 2026 | 187.77M |
| September 15, 2026 | 200.28M |
| September 14, 2026 | 256.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 224.73B |
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.26M |
| Revenue (Quarterly) | 2.956M |
| Total Expenses (Quarterly) | 23.21M |
| EPS Diluted (Quarterly) | -0.93 |
| Gross Profit Margin (Quarterly) | 99.19% |
| Profit Margin (Quarterly) | -685.3% |
| Earnings Yield | -1.26% |
| Normalized Earnings Yield | -1.256 |